Clinical Trials Browser

Phase 2 × pomalidomide × Plasma cell × Clear all

NCT06948084 2026-03-18

Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse

Phase 2 Not yet recruiting

Multiple Myeloma

NCT04883242 2026-03-13

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma

NCT04270175 2026-02-27

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Phase 2 Active not recruiting

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease

NCT01745640 2026-02-05

IFM2010-02

Phase 2 Completed

Chromosome 17 deletion, Multiple Myeloma

NCT02718833 2026-01-22

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma, Recurrence

NCT05922501 2026-01-14

ISABELA

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT07312188 2025-12-31

A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT05789303 2025-12-22

Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma

Phase 2 Recruiting

Multiple Myeloma

NCT04850599 2025-12-18

Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma

Phase 2 Active not recruiting

Multiple Myeloma

NCT07227311 2025-11-12

A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

Phase 2 Not yet recruiting

Multiple Myeloma

NCT04126200 2025-11-06

DREAMM5

Phase 2 Active not recruiting

Multiple Myeloma

NCT03590652 2025-10-21

Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma

Phase 2 Terminated

Multiple Myeloma, Neoplasms

NCT05911321 2025-10-20

Isa-Pom-Dex in Elderly/Frail Subjects With RRMM

Phase 2 Active not recruiting

Multiple Myeloma, Recurrence

NCT04176718 2025-10-07

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT04302324 2025-10-01

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

Phase 2 Active not recruiting

Multiple Myeloma

NCT03731832 2025-09-30

Pomalidomide, Ixazomib, and Dexamethasone With or Without Intensification by Cyclophosphamide in Relapsed or Refractory Multiple Myeloma

Phase 2 Completed

Multiple Myeloma

NCT01745588 2025-09-11

Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma

Phase 2 Completed

Multiple Myeloma

NCT04191616 2025-09-04

SELECT

Phase 2 Completed

54 enrolled 17 charts

Multiple Myeloma, Recurrence

NCT05208307 2025-09-02

Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma

Phase 2 Recruiting

Multiple Myeloma

NCT05288062 2025-08-20

Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma

Phase 2 Terminated

17 enrolled 9 charts

Smoldering Multiple Myeloma, Multiple Myeloma

NCT04124497 2025-08-08

DPd

Phase 2 Active not recruiting

Chromosome 17 deletion, Multiple Myeloma

NCT04508790 2025-08-07

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Phase 2 Recruiting

Multiple Myeloma

NCT03713294 2025-06-24

Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma

Phase 2 Completed

37 enrolled 11 charts

Multiple Myeloma

NCT01946477 2025-06-06

POM MM 014

Phase 2 Completed

Multiple Myeloma, Neoplasms, Plasmacytoma

NCT02719613 2025-06-05

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

Phase 2 Active not recruiting

Multiple Myeloma

NCT04892446 2025-05-02

Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

Phase 2 Terminated

36 enrolled 17 charts

Multiple Myeloma

NCT04700176 2025-02-25

A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multiple Myeloma

Phase 2 Terminated

1 enrolled 14 charts

Multiple Myeloma

NCT04895917 2025-02-20

DarPAL

Phase 2 Terminated

Immunoglobulin Light-chain Amyloidosis

NCT04835129 2025-02-07

IMPEDE

Phase 2 Recruiting

Multiple Myeloma

NCT05669989 2025-01-23

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

Phase 2 Active not recruiting

Multiple Myeloma

NCT02406222 2024-12-05

MUKseven

Phase 2 Active not recruiting

Multiple Myeloma, Recurrence

NCT05050305 2024-07-16

Marizomib Central Nervous System (CNS)

Phase 2 Withdrawn

Multiple Myeloma

NCT05478993 2024-01-31

SPODUMENE

Phase 2 Unknown

Multiple Myeloma

NCT02188368 2023-11-03

Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

Phase 2 Terminated

Multiple Myeloma

NCT02294357 2023-11-01

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Phase 2 Terminated

Multiple Myeloma, Recurrence

NCT02547662 2023-10-30

Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia

Phase 2 Completed

17 enrolled 13 charts

Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Plasmacytoma

NCT04843579 2023-10-25

ClaSPd

Phase 2 Terminated

4 enrolled 9 charts

Multiple Myeloma, Neoplasms, Plasma Cell

NCT03202628 2023-09-21

Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma

Phase 2 Completed

8 enrolled 14 charts

Multiple Myeloma

NCT03215524 2023-08-04

DCDP

Phase 2 Completed

Multiple Myeloma

NCT05432414 2023-01-31

PVd Versus Vd in NDMM Patients With RI

Phase 2 Unknown

Multiple Myeloma

NCT05509374 2022-08-22

KMM2002

Phase 2 Unknown

Multiple Myeloma

NCT03841565 2022-06-15

Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

Phase 2 Withdrawn

Multiple Myeloma

NCT03104270 2022-03-31

Combination Study for High Risk Multiple Myeloma Patients

Phase 2 Terminated

Multiple Myeloma

NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Phase 2 Unknown

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

NCT02045017 2021-08-27

Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency

Phase 2 Completed

Multiple Myeloma, Renal Insufficiency

NCT04584307 2021-08-23

Immuno-POWER

Phase 2 Withdrawn

Multiple Myeloma

NCT03520985 2021-06-10

OptiPOM

Phase 2 Terminated

Multiple Myeloma

NCT01177735 2021-04-22

Pomalidomide in Gene Expression Profiling (GEP)-Defined High-risk Multiple Myeloma

Phase 2 Completed

71 enrolled 7 charts

Multiple Myeloma, Recurrence

NCT04243109 2020-01-28

POCODEX

Phase 2 Terminated

Multiple Myeloma

NCT02176213 2019-06-18

Study of Pomalidomide, Cyclophosphamide, Dexamethasone in Relapsed/Refractory Multiple Myeloma

Phase 2 Completed

Multiple Myeloma, Recurrence